July 26, 2021 10:24 AM 26 seconds read

After COVID-19, BioNTech Plans To Develop an mRNA Vaccine To Prevent Malaria

by Vandana Singh Benzinga Editor
Follow
  • BioNTech SE BNTX has announced that it plans to develop an mRNA-based vaccine to prevent Malaria, a mosquito-borne illness.
  • The Company aims to begin clinical trials for the shot by the end of 2022.
  • BioNTech said it would assess multiple vaccine candidates that target the circumsporozoite protein (CSP), as well as new antigens discovered in pre-clinical research.
  • Price Action: BNTX shares are up 3.72% at $292.44 during the market session on the last check Monday.
Loading...
Loading...
BNTX Logo
BNTXBioNTech SE
$92.28-0.06%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
38.90
Growth
-
Quality
-
Value
57.83
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsmalaria
Comments

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved